| 0.2893 0.002 (0.63%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.4  |
1-year : | 0.45 |
| Resists | First : | 0.34 |
Second : | 0.38 |
| Pivot price | 0.31 |
|||
| Supports | First : | 0.27 | Second : | 0.22 |
| MAs | MA(5) : | 0.29 |
MA(20) : | 0.32 |
| MA(100) : | 0.4 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.9 |
D(3) : | 23 |
| RSI | RSI(14): 40 |
|||
| 52-week | High : | 0.89 | Low : | 0.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PAVM ] has closed above bottom band by 23.9%. Bollinger Bands are 13.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.29 - 0.29 | 0.29 - 0.29 |
| Low: | 0.28 - 0.28 | 0.28 - 0.28 |
| Close: | 0.29 - 0.29 | 0.29 - 0.29 |
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Wed, 10 Dec 2025
Ascendiant Capital Maintains PAVmed (PAVM) Buy Recommendation - Nasdaq
Tue, 18 Nov 2025
Is PAVmed (NASDAQ:PAVM) Using Debt Sensibly? - simplywall.st
Fri, 14 Nov 2025
PAVmed Inc. (NASDAQ:PAVM) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 13 Nov 2025
Earnings call transcript: PAVmed Q3 2025 reports net loss, stock dips - Investing.com
Thu, 13 Nov 2025
PAVmed Inc (PAVM) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... - Yahoo Finance
Thu, 13 Nov 2025
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | -12 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.764e+007 (%) |
| Held by Institutions | 1.931e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -152000 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.41 |
| Profit Margin | 10 % |
| Operating Margin | 672.4 % |
| Return on Assets (ttm) | -96 % |
| Return on Equity (ttm) | 880 % |
| Qtrly Rev. Growth | 17.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.003e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.73 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 585080 |
| Forward Dividend | 256470 |
| Dividend Yield | 202240000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|